ArticlePLOS global public health2026
Human papillomavirus (HPV) vaccine uptake and its associated factors among adolescent girls in Kathmandu District, Nepal: A cross-sectional study.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HPV causes over 95% of cervical cancer globally. In Nepal, cervical cancer is the second most common cancer with a crude incidence of 14.2 per 100,000 women, and HPV vaccination for 14-year-old girls began nationwide in 2023. This study assessed HPV vaccine uptake and its associated factors among adolescent girls in Kathmandu district. A cross-sectional study was conducted using multistage cluster random sampling. From 770 schools across eight municipalities where the vaccine available, 142 were selected, with ten 14-15-year-old girls each school. Data were collected using a supervised self-administered questionnaire. HPV vaccine uptake was defined as receipt of two doses within six months. Factors associated with uptake were analysed using Poisson regression with generalized estimating equations, accounting for clustering and sample weights. The prevalence of HPV vaccine uptake was 12.74% (CI: 7.2-21.4). Girls attending private schools had lower uptake than those in public schools (APR: 0.05; CI: 0.02-0.13), while 15-year-old girls had higher uptake than 14-year-olds (APR: 2.28; CI: 1.49-3.50). Lower uptake was observed among girls whose fathers were daily wage labour (APR: 0.59; CI: 0.39-0.90), self-employed (APR: 0.59; CI: 0.39-0.90), or employed abroad (APR: 0.65; CI: 0.43-0.97), whereas higher uptake was noted among girls whose mothers were employed in government jobs (APR: 2.70; CI: 1.55-4.69), private jobs (APR: 2.15; CI: 1.11-4.14), or abroad (APR: 2.58; CI: 1.31-3.86). Good knowledge of HPV infection (APR: 1.88; CI: 1.13-3.15) and good or moderate knowledge of the HPV vaccine (APR: 2.73; CI: 1.33-5.60 and APR: 2.02; CI: 1.07-3.82) were also associated with higher uptake. In conclusion uptake was higher among public school students, older adolescents, and those with working mothers or good HPV knowledge, highlighting the need for targeted interventions to improve awareness, school-based education, and access to vaccination services.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.